AN2 Therapeutics Phase 3 Trial Pause Impacts Stock
AN2 Therapeutics' stock rating was downgraded by Oppenheimer after pausing its Phase 3 trial. The company is reassessing and discussing ...
- Latest
- Trending
AN2 Therapeutics' stock rating was downgraded by Oppenheimer after pausing its Phase 3 trial. The company is reassessing and discussing ...
FDA approves Takeda's EOHILIA as first-line treatment for Eosinophilic Esophagitis. Groundbreaking oral therapy offers hope for improved quality of life.
Kintara Therapeutics has launched a clinical trial for REM-001, a promising treatment for cutaneous metastatic breast cancer. The trial aims ...
Tonix Pharmaceuticals receives FDA clearance for its OASIS trial, evaluating the efficacy of TNX-102 SL in treating acute stress reactions ...
AN2 Therapeutics voluntarily pauses enrollment in its epetraborole clinical trial due to lower efficacy. Safety is not a concern. The ...
Biopharmaceutical company Atossa Genetics receives Buy rating from H.C. Wainwright, with a new price target of $4.00. The company's promising ...
Asian stocks traded in a narrow range due to many major markets being closed for Chinese New Year. Australian market ...
Shares of pharmaceutical firm CSL are set for their worst day in four months as the company announced disappointing results ...
Discover how surgeons are using real-time MRIs to enhance the safety and efficacy of gene therapy surgeries, revolutionizing the approach ...
Discover how Virtual Reality (VR) is revolutionizing gastrointestinal healthcare by modulating the mind-gut connection in this informative article. #VR #healthtech ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.